Celator Pharmaceuticals — Corporate Update (December 2014)
62 slides from Celator Pharmaceuticals's corporate update, Dec 8, 2014
Slide 1: Corporate Update December 6, 2014
® Corporate Update December 6, 2014 ®
Slide 2: Safe Harbor
® SAFE HARBOR To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Secur
Slide 3: Agenda
® AGENDA 8:00 – 8:10 pm: Welcome & Introduction Scott Jackson Chief Executive Officer 8:10 – 8:20 pm: CombiPlex Update & Review of CPX - 351 Preclinical Data Selected for Presentation at the American Society of Hematology meeting Dr. Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Office
Slide 4: Welcome & Introduction
® 4 Welcome & Introduction Scott Jackson Chief Executive Officer
Slide 5: Our Mission: To Improve and Extend the Lives of Patients with Cancer
® OUR MISSION: TO IMPROVE AND EXTEND THE LIVES OF PATIENTS WITH CANCER BY TRANSFORMING THE SCIENCE OF COMBINATION THERAPY 5
Slide 6: Developing Cutting Edge Technologies for Cancer Treatment
® DEVELOPING CUTTING EDGE TECHNOLOG IES FOR CANCER TREATMENT • CombiPlex ® is a combination - optimizing technology platform • Elevated, prolonged, selective exposure of synergistic drug ratios to tumors • Broadening applications for CombiPlex • Evaluating 3 novel targeted combination products, that
Slide 7: Celator's Proprietary Oncology Pipeline
® 7 CELATOR’S PROPRIETARY ONCOLOGY PIPELINE CPX - 1 Irinotecan:Floxuridine CPX - 351 Cytarabine:Daunorubicin CPX - 8 (HDPN) Taxane Nanoparticle Research Preclinical Phase 1 Phase 2 Proprietary Technology Platforms Phase 3 Colorectal Cancer Secondary Acute Myeloid Leukemia (Ongoing) Solid Tumors Nove
Slide 8: Building a Broad Pipeline from the CombiPlex Platform
® BUILDING A BROAD PIPELINE FROM THE COMBIPLEX ® PLATFORM • Advancing CombiPlex to widen its application to molecularly targeted therapies • Combinations targeting signaling pathways (i.e. inhibitors of PI3K/AKT/ mTOR pathway and inhibitors of Ras / Raf /MEK/ERK pathway) • Combinations of existing c
Slide 9: Phase 3 Study Design in sAML
® 9 CPX - 351 PHASE 3 STUDY DESIGN IN S AML STUDY ACHIEVED TARGET ENROLLMENT AHEAD OF SCHEDULE Eligibility • Confirmation of sAML according to the World Health Organization (WHO) criteria with certain exclusions • Age 60 - 75 years • Able to tolerate intensive chemo • PS 0 - 2 Randomization CPX - 35
Slide 10: Advantages of the Phase 3 Study
® ADVANTAGES OF THE CPX - 351 PHASE 3 STUDY 10 • AML is heterogeneous • Single arm studies used to design Phase 3 studies may not be predictive • Two randomized, controlled clinical studies were conducted to identify patient populations to pursue in Phase 3; initial registration study is in sAML pat
Slide 11: Advantages of the Phase 3 Study
® • Benefit seen with CPX - 351 vs 7+3 is consistent across all metrics – higher response rate, reduced early mortality and improved overall survival • A positive Phase 3 result can be achieved with half the overall survival observed in the Phase 2 (the population that matches the eligibility being
Slide 12: Selected Phase 3 AML Product Candidates
® SELECTED PHASE 3 AML PRODUCT CANDIDATES Celator (CPXX) Sunesis (SNSS) Cyclacel (CYCC) Ambit (AMBI) Product CPX - 351 vosaroxin (Qinprezo) sapacitabine quizartinib Patient Population secondary AML >60 and <75 years of age Relapsed/refractory AML > 18 years of age First - line >70 years of age FLT3
Slide 13: CombiPlex Update & Preclinical Data Being Presented at ASH
® 13 CombiPlex ® Update & CPX - 351 Preclinical Data Being Presented at ASH Lawrence Mayer, Ph.D. Founder, President & Chief Scientific Officer
Slide 14: CombiPlex: Rationale for Role of Drug Delivery in Targeted Combinations
® COMBIPLEX®: RATIONALE FOR ROLE OF DRUG DELIVERY IN DEVELOPMENT OF TARGETED AGENT COMBINATIONS 14 Conventional Combinations CombiPlex ® Many require simultaneous target inhibition Harmonized PK and tumor cell exposure to both agents Toxicity complications observed with many targeted agent combinati
Slide 15: Combinations Identified for CombiPlex Application to Targeted Agents
® COMBINATIONS IDENTIFIED FOR COMBIPLEX ® APPLICATION TO MOLECULARLY TARGETED AGENTS Histone deacetylase inhibitors plus Hypomethylating agents • Promising early clinical evidence of favorable interaction • Optimal efficacy with simultaneous exposure • Dose limiting toxicity (encephalopathy) of comb
Slide 16: CombiPlex May Address Shortcomings for Targeted Combinations
® COMBIPLEX ® MAY ADDRESS A VARIETY OF SHORTCOMINGS FOR MOLECULARLY TARGETED COMBINATIONS UNDER INVESTIGATION 16 ISSUE CombiPlex ® PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK Docetaxel ) plus HSP90 inhibitors HDAC inhibitors plus Hypomethylating agents Pathway cross - talk requires concurrent inhibition
Slide 17: CombiPlex May Address Shortcomings for Targeted Combinations
® COMBIPLEX ® MAY ADDRESS A VARIETY OF SHORTCOMINGS FOR MOLECULARLY TARGETED COMBINATIONS UNDER INVESTIGATION 17 ISSUE CombiPlex ® PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK Docetaxel ) plus HSP90 inhibitors HDAC inhibitors plus Hypomethylating agents Pathway cross - talk requires concurrent inhibition
Slide 18: CombiPlex May Address Shortcomings for Targeted Combinations
® COMBIPLEX ® MAY ADDRESS A VARIETY OF SHORTCOMINGS FOR MOLECULARLY TARGETED COMBINATIONS UNDER INVESTIGATION 18 PI3K/AKT/ mTOR plus Ras / Raf /MEK/ERK Docetaxel ) plus HSP90 inhibitors HDAC inhibitors plus Hypomethylating agents Pathway cross - talk requires concurrent inhibition for optimal effica
Slide 19: Prodrug Nanoparticle Formulation Increases Plasma Drug Concentration
® Hours After Administration 0 5 10 15 20 25 Percent Injected Dose 0.0001 0.001 0.01 0.1 1 10 100 1000 Docetaxel prodrug AUY922 prodrug Free AUY922 Free Docetaxel 19 PRODRUG NANOPARTICLE FORMULATION OF DOCETAXEL AND AUY922 DRAMATICALLY INCREASE PLASMA DRUG CONCENTRATION Plasma concentrations of AUY9
Slide 20: American Society of Hematology Poster Presentations
® American Society of Hematology Poster Presentations 20
Slide 21: CPX-351: ADME (Absorption, Distribution, Metabolism and Excretion)
® CPX - 351: ADME (ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION) • CPX - 351 Markedly Reduces Renal and Hepatic Clearance Rates for Cytarabine ( Cyt ) and Daunorubicin ( Daun ) in Rats with an Associated Decrease in Excretory and Metabolic Burden Despite Providing Dramatic Increases in Systemi
Slide 22: Slower Drug Elimination Reduces Burden on Excretory/Metabolic Systems
® SLOWER DRUG ELIMINATION FOR CPX - 351 COMPARED TO FREE DRUGS REDUCES BURDEN ON EXCRETORY / METABOLIC SYSTEMS 22 DAUNORUBICIN CYTARABINE
Slide 23: QWBA Reveals Decreased Distribution and Bone Marrow Accumulation: Cytarabine
® QWBA REVEALS DECREASED DRUG DISTRIBUTION TO MOST TISSUES AND INCREASED ACCUMULATION IN BONE MARROW CYTARABINE Treatment Hours after Administration [ 14 C]Cytarabine 1 24 Non-Liposomal CPX-351 23
Slide 24: QWBA Reveals Decreased Distribution and Bone Marrow Accumulation: Daunorubicin
® QWBA REVEALS DECREASED DRUG DISTRIBUTION TO MOST TISSUES AND INCREASED ACCUMULATION IN BONE MARROW 24 DAUNORUBICIN Treatment Hours after Administration [ 14 C]Daunorubicin 1 48 Non-Liposomal CPX-351
Slide 25: Conclusions from Preclinical ADME
® CONCLUSIONS FROM PRECLINICAL ADME • The slower drug excretion of Cyt and Daun for CPX - 351 suggests that the burden on excretory and metabolic systems may be reduced for CPX - 351 • CPX - 351 limits early tissue distribution of Cyt and Daun compared to the drugs administered as the non - liposoma
Slide 26: CPX-351 Update
® CPX - 351 UPDATE DR. JEFFREY LANCET SECTION CHIEF OF LEUKEMIA, DEPARTMENT OF MALIGNANT HEMATOLOGY, MOFFITT CANCER CENTER 26
Slide 27: Timeline of Progress in AML
® Timeline of “progress” in AML 1950s - 1960s 1970s 1980s 1990s 2000s 2010s Daunorubicin Cytarabine Daunorubicin + Cytarabine Idarubicin + Cytarabine High - dose Cytarabine Gemtuzumab Cladribine Vosaroxin CPX - 351 Sapacitabine Midostaurin HMAs HDAC inhibitors 27
Slide 28: AML Survival in Older Patients
® AML survival: patients ≥ 60 years Burnett et al. Semin Hematol 2006: 43(2):96 - 106 0 1 2 3 4 5 6 7 8 0.0 0.2 0.4 0.6 0.8 1.0 Years Survival Probability 28
Slide 29: Issues Delaying Development of Effective New Therapy in AML
® Issues delaying the development of effective new therapy in AML • Discovery of molecular anomalies have not yet translated into clear therapeutic targets • Lack of molecular data applied retrospectively to predict response • Trial Design • Empiric testing in a heterogeneous disease • Especially wi
Slide 30: CPX-351 Liposome Composition
® CPX - 351 • 100 nm bilamellar liposomes • 5:1 molar ratio of cytarabine to daunorubicin • 1 unit = 1.0 mg cytarabine plus 0.44 mg daunorubicin 30
Slide 31: Pharmacological Basis of CPX-351
® Pharmacological Basis of CPX - 351 CPX - 351 liposome delivers 5:1 molar ratio for >24 hours Hours After Administration 0 20 40 60 80 100 120 140 160 180 Bone Marrow Cytarabine ( g/ml) 0 1 2 3 CPX-351 Free drug cocktail Cytarabine Accumulates and persists in the bone marrow Preferential uptake a
Slide 32: Phase 1 Study of CPX-351 in AML
® Phase 1 study of CPX - 351 in AML • First in human study • Relapsed, refractory AML • Dose escalation – planned up to 134 units/m 2 • Primary endpoints – safety, maximum tolerated dose 32
Slide 33: Phase 1 Study: Key Findings
® Phase 1 study of CPX - 351 in AML: Key Findings • Safety • Dose limiting toxicity in 3 of 6 patients at 134 units/m 2 • Congestive heart failure, hypertension, prolonged cytopenias • Other most common grade 3 - 4 toxicities • Rash, liver function abnormalities, • Clinical congestive heart failure
Slide 34: Pharmacokinetics
® Pharmacokinetics 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 0 24 48 72 96 120 144 168 TIME (hr) Cytarabine Daunorubicin Mean plasma concentration after the day 5 infusion among patients receiving 24 units/m^2 CPX-351 (n=3) D & A detectable 7 days at completion of infusion Fixed molar ra
Slide 35: Randomized Phase 2 Trial vs 7+3 in Older Untreated AML
® Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Eligibility • Newly diagnosed • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 (n=85) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 (n=41) Daunorubicin 60 mg/m 2 Cytarabine 100
Slide 36: Key Demographic Features
® Key Demographic Features CPX - 351 7+3 n=85 n=41 Gender Male 53 (62.4%) 25 (61.0%) Race Caucasian 76 (89.4%) 39 (95.1%) Risk Standard Risk 28 (32.9%) 14 (34.1%) High Risk 57 (67.1%) 27 (65.9%) Age Group ≥70yrs 34 (40.0%) 15 (36.6%) Median (yrs) 68.0 68.0 AML Type De novo AML 52 (61.2%) 22 (53.7%)
Slide 37: Randomized Phase 2 Trial Results vs 7+3
® Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Parameter CPX - 351 (n=84) “7+3” Regimen (n=41) CR (%) 41 (48.8) 20 (48.8) CRi (%) 15 (17.9) 1 (2.4) CR + CRi (%) 56 (66.6) 21 (51.2) 60 - d mortality (%) 4 (4.7) 6 (14.6) CR + CRi (%) in s - AML 19 (57.5) 6 (31.6) s - AML media
Slide 38: Overall Survival by Treatment Arm
® Randomized Phase 2 Trial of CPX - 351 vs “7+3” in Older Untreated AML Lancet et al, Blood 2014; 123:3239 sAML All Patients Overall Survival Overall Survival by treatment arm 0% 20% 40% 60% 80% 100% 0 12 24 36 48 Months from randomization Arm A: CPX - 351 Arm B: 7+3 Deaths / N 58 / 85 27 / 41 Media
Slide 39: Safety
® Safety CPX - 351 (n=85) 7+3 (n=41) n (%) n (%) Grade 3/4 Grade 5 Grade 3/4 Grade 5 Febrile Neutropenia 54 (63.5) 0 (0.0) 21 (51.2) 0 (0.0) Infections 60 (70.6) 3 (3.5) 18 (43.9) 3 (7.3) Bacteraemia 30 (35.3) 0 (0.0) 8 (19.5) 0 (0.0) Epistaxis 6 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) Petechiae 1 (1.2) 0 (0.
Slide 40: Outcomes in Patients with Prior Hypomethylating Agent Exposure
® Outcomes in patients with prior hypomethylating agent exposure Prior Hypomethylating Agent Treatment CPX - 351 n=33 (%) 7+3 n=19 (%) +HMA 13 (39%) - HMA 20 (61%) +HMA 7 (37%) - HMA 12 (63%) Responses 7 (54) 12 (60) 2 (29) 4 (33) CR 3 (23) 9 (45) 2 (29) 4 (33) CRi 4 (31) 3 (15) 0 0 40
Slide 41: Randomized Phase 2 Trial vs Salvage in 1st Relapse AML
® Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Eligibility • 1st Relapse • Initial CR ≥1 month • Ages 18 - 65 • Stratified by European Prognostic Index • PS 0 - 2 CPX - 351 (n=81) 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations Salvage (as per investigat
Slide 42: Phase 2 Relapse AML Results
® Randomized Phase 2 Trial of CPX - 351 vs Salvage in 1 st Relapse AML Overall (n=125) EPI Poor - Risk ( n=85) CPX - 351 (n=81) Salvage (n=44) CPX - 351 (n=56) Salvage (n=29) Response Rate 49.4% 40.9% 39.3% 27.6% 60 - Day Mortality 14.8% 15.9% 16.1% 24.1% EFS (median, mos.) 4.0 1.4 1.9 1.2 OS (media
Slide 43: Potential Reasons for Greater Benefit in High-Risk AML
® Potential reasons why CPX - 351 has a greater benefit in High - Risk AML Patients • Altered signaling/cell cycle control checkpoints • 5:1 molar ratio: constant cytarabine excess → daunorubicin DNA damage without blocking cell cycle progression to S - phase where cytarabine action occurs preventin
Slide 44: Randomized Phase 3 Trial vs 7+3 in Older Patients with sAML
® Randomized Phase 3 Trial of CPX - 351 vs “7+3” in Older Patients with sAML Eligibility • Previously untreated sAML or tAML • Ages 60 - 75 • Able to tolerate intensive therapy • PS 0 - 2 CPX - 351 100 units/m 2 IV days 1, 3, 5 Up to 2 inductions and 2 consolidations 7+3 Daunorubicin 60 mg/m 2 Cytar
Slide 45: Phase II sAML Definition: Phase II vs. Phase III
® CPX - 351 vs 7+3 Phase II study: sAML Definition Phase II vs. Phase III *Patient 12 - 004, originally identified as a de novo patient, was diagnosed with Philadelphia chromosome and was not assessed for response Phase III study will use WHO criteria for confirmation of secondary AML 16 patients ad
Slide 46: What Makes AML-301 Unique from Other Phase 3 AML Studies
® What makes AML - 301 unique from other phase 3 AML studies? • Based upon a prior randomized study • Based upon a prior study that identified a distinct group of patients found to benefit from CPX - 351 (secondary AML) • Primary endpoint (overall survival) was modeled upon the primary endpoint from
Slide 47: Endpoints
® Endpoints • Primary • Overall survival with >90% power to detect HR = 0.63 • Detect a 37% decrease in the rate of death with CPX - 351 over the course of the study. • Secondary • Response rate (CR+CRi) • Event - free survival • 60 day mortality • Leukemia clearance rate 47
Slide 48: Power Calculations
® Power Calculations Power Hazard Ratio 70 0.726 75 0.712 80 0.697 85 0.679 90 0.657 93.7 0.635 Arm B Rate 31% 42% Power Arm A Rate (%) Difference (%) Arm A Rate (%) Difference (%) 70 46.5 15.5 57.9 15.9 75 47.4 16.4 58.8 16.8 80 48.4 17.4 59.8 17.8 85 49.6 18.6 60.9 18.9 90 51.0 20.0 62.3 20.3 95 5
Slide 49: Final Induction Response Rate Analysis
® Final Induction Response Rate Analysis • When: • 2Q 2015 • What: • CPX - 351 CR+Cri /n (%) vs. Control CR+CRi /n (%) • No p - value will be calculated • Comments: • Final induction response rate analysis was prospectively defined in the Phase 3 protocol and statistical analytical plan • The analys
Slide 50: Secondary AML Patient Population Response Rate
® Secondary AML Patient Population Response Rate n=58 CPX - 351 (n=39) 7+3 (n=19) CR+CRi 1 (%) 73.7 42.1 CR only 1 (%) 50.0 42.1 CRi only 1 (%) 23.7 0 1 Patient 12 - 004, originally identified as a de novo patient, was diagnosed with Philadelphia chromosome and was not assessed for response 50
Slide 51: Secondary AML Patient Population Early Mortality
® Secondary AML Patient Population Early Mortality n=58 CPX - 351 (n=39) 7+3 (n=19) Early mortality (d=60) (%) 2.6 26.3 51
Slide 52: Secondary AML Patient Population Median Overall Survival
® Secondary AML Patient Population Median Overall Survival n = 58 CPX - 351 ( n=39 1 ) 7+3 (n=19 2 ) All Patients 12.1 months 6.3 months Responders 15.4 months (n=28) 9.4 months (n=8) Non Responders 9.2 months 3.2 months 1 Patient 12 - 004, originally identified as a de novo patient, was diagnosed w
Slide 53: Secondary AML Summary of Important Endpoints
® Secondary AML Patient Population Summary of Important Endpoints n = 58 CPX - 351 ( n=39 1 ) 7+3 (n=19 2 ) Morphologic Leukemia Free State 3 35/39 (89.7%) 12/17 (70.6%) Response Rate ( CR+CRi ) (%) 73.7 42.1 Duration of Remission (Months) 6.2 4.3 60 Day Mortality (%) 2.6 26.3 Median Event Free Surv
Slide 54: American Society of Hematology Poster Presentations
® American Society of Hematology Poster Presentations 54
Slide 55: CPX-351: HR-MDS or AML Patients at High Risk of Treatment-Related Mortality
® CPX - 351: HR - MDS OR AML PATIENTS AT HIGH - RISK OF TREATMENT - RELATED MORTALITY • Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX - 351) for Adults with Untreated High - Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment - Related Mort
Slide 56: HR-MDS or AML Patients at High Risk of Treatment-Related Mortality
® • Patients with AML/MDS at high risk of early mortality following treatment are often given palliative care with no serious attempt to induce remissions. • These patients are heterogeneous and causes of early mortality include progressive AML/MDS and treatment - induced toxicities. • The TRM scori
Slide 57: HR-MDS or AML Patients at High Risk of Treatment-Related Mortality
® • Patients were randomized to receive CPX - 351 at 32 or 64 units/m2 by 90 - minute infusion on days 1, 3, and 5. • The 64 unit/m2 dose level observed 3 early deaths and 2 CR among 9 patients. • Based on a comparison with historic controls who principally received 7+3 or high - dose cytarabine - b
Slide 58: Question & Answer Session
® Question & Answer Session 58
Slide 59: Closing Remarks
® Closing Remarks SCOTT JACKSON CHIEF EXECUTIVE OFFICER 59
Slide 60: Creating Shareholder Value
® CREATING SHAREHOLDER VALUE • Execution of the Phase 3 study and preparation for regulatory submission and commercialization • Celator to commercialize CPX - 351 in the US • Seek ex - US partner • Continue to evaluate the potential of CPX - 351 in other patient populations (e.g. AML and other hemat
Slide 61: 2014-2016 Expected Milestones
® 2014 - 2016 EXPECTED MILESTONES POTENTIAL NDA FILING FOR CPX - 351 IN 2H2016 Phase 3 Remission Rate Start Technology Platform Programs Phase 3 Overall Survival Complete Technology Platform Programs NDA Submission 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 2014 2015 2016 First Relapse Phase 2 Publication ASH
Slide 62: Thank You
® 62 THANK YOU!!!
Celator Pharmaceuticals — Corporate Update (December 2014) on 6ix